Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2019, Article ID 8349793, 4 pages
https://doi.org/10.1155/2019/8349793
Case Report

Treating Penile Cancer in the Immunotherapy and Targeted Therapy Era

UCLA Medicine Education Office, RRUCLA Medical Center, 757 Westwood Plaza, Suite 7501, Los Angeles, CA 90095-7417, USA

Correspondence should be addressed to Gavin Hui; ude.alcu.tendem@iuhg

Received 17 October 2018; Accepted 18 February 2019; Published 25 March 2019

Academic Editor: Ossama W. Tawfik

Copyright © 2019 Gavin Hui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer Statistics, 2018,” CA: A Cancer Journal for Clinicians, vol. 68, no. 1, pp. 7–30, 2018. View at Publisher · View at Google Scholar · View at Scopus
  2. A. M. Mosconi, F. Roila, G. Gatta, and C. Theodore, “Cancer of the penis,” Critical Reviews in Oncology/Hematology, vol. 53, no. 2, pp. 165–177, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Marconnet, J. Rigaud, and O. Bouchot, “Long-term followup of penile carcinoma with high risk for lymph node invasion treated with inguinal lymphadenectomy,” Journal of Urology, vol. 183, no. 6, pp. 2227–2232, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. R. J. Dickstein, M. F. Munsell, L. C. Pagliaro, and C. A. Pettaway, “Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy,” BJU International, vol. 117, no. 1, pp. 118–125, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. L. C. Pagliaro, D. L. Williams, D. Daliani et al., “Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study,” Journal of Clinical Oncology, vol. 28, no. 24, pp. 3851–3857, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Wang, C. A. Pettaway, and L. C. Pagliaro, “Treatment for metastatic penile cancer after first-line chemotherapy failure: analysis of response and survival outcomes,” Urology, vol. 85, no. 5, pp. 1104–1110, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. B. C. Carthon, C. S. Ng, C. A. Pettaway, and L. C. Pagliaro, “Epidermal growth factor receptor–targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis,” BJU International, vol. 113, no. 6, pp. 871–877, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Necchi, N. Nicolai, M. Colecchia et al., “Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis,” Journal of Clinical Oncology, vol. 29, no. 22, pp. e650–e652, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. Udager, T. Y. Liu, S. L. Skala et al., “Frequent PD-L1 Expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches,” Annals of Oncology, vol. 27, no. 9, pp. 1706–1712, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Fessas, H. Lee, S. Ikemizu, and T. Janowitz, “A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab,” Seminars in Oncology, vol. 44, no. 2, pp. 136–140, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. J. R. Brahmer, C. Lacchetti, B. J. Schneider et al., “Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline,” Journal of Clinical Oncology, vol. 36, no. 17, pp. 1714–1768, 2018. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Gu, Y. Zhu, and D. Ye, “Beyond chemotherapy for advanced disease—the role of EGFR and PD-1 inhibitors,” Translational Andrology and Urology, vol. 6, no. 5, pp. 848–854, 2017. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Di Lorenzo, S. Perdonà, C. Buonerba et al., “Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study,” Journal of Translational Medicine, vol. 11, no. 1, p. 161, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Cocks, D. Taheri, M. W. Ball et al., “Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort,” Human Pathology, vol. 59, pp. 55–61, 2017. View at Publisher · View at Google Scholar · View at Scopus